The collaboration will provide comprehensive research capabilities to Neurogene, enabling the company and university to accelerate platform approaches that improve upon existing gene therapy technologies focused on neurodevelopmental diseases.

Under the terms of the collaboration, Neurogene will provide financial support for the lab of Stuart Cobb, PhD, at the University of Edinburgh, in exchange for the right to license any applicable intellectual property at agreed upon economic terms. Neurogene will be responsible for late stage preclinical and all clinical development of any products generated under the collaboration.

Cobb also serves as the chief scientific officer at Neurogene.

The collaboration has been supported by Edinburgh Innovations, the University of Edinburgh's commercialization service.

Neurogene nabs $115M in series B financing
Neurogene has completed $115 million in series B financing, which will be used to advance various aspects of the company's gene therapy programs...

Regulatory Roundup: Designations come through before year's end
This week's Regulatory Roundup covers activities from November 30 to December 4 and is filled with breakthrough, orphan, and rare disease designations...